SCHEMBL584656

SCHEMBL584656

CCCCCCCCCCCCCCCCC(C(=O)O)C(=O)C(O)CO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.60
FFAR1 O14842 2/20 0.60
MAPT P10636 2/20 0.48
LCK P06239 1/20 0.48
PPARD Q03181 1/20 0.48
ZDHHC20 Q5W0Z9 1/20 0.48
ZDHHC2 Q9UIJ5 1/20 0.48
FFAR4 Q5NUL3 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
LMNA P02545 2/20 0.45
CYP2D6 P10635 2/20 0.43
SPHK1 Q9NYA1 1/20 0.43
GMNN O75496 1/20 0.43
POLB P06746 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43
BLM P54132 1/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1237975 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL425589 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL165537 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL168064 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL167865 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL17646227 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL167222 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL5740376 0.98 GPR84 (0.57) GPR84FFAR1MAPTLCKPPARD
SCHEMBL2858482 0.96 GPR84 (0.56) GPR84FFAR1MAPTLCKPPARD
SCHEMBL6910867 0.95 GPR84 (0.55) GPR84FFAR1MAPTLCKPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1053 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12611407-B2 Gastro-resistant high-strength formulation containing posaconazole ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) 2026-04-28 US claimed
EP-4181883-B1 GRANULES CONTAINING POSACONAZOLE TIEFENBACHER ALFRED E GMBH & CO KG (DE) 2025-11-19 EP claimed
US-20240390363-A1 GRANULES CONTAINING POSACONAZOLE ALFRED E. TIEFENBACHER (GMBH AND CO. KG) (DE) 2024-11-28 US claimed
EP-3590505-B1 GASTRO-RESISTANT FORMULATION CONTAINING POSACONAZOLE TIEFENBACHER ALFRED E GMBH & CO KG (DE) 2024-11-06 EP claimed
US-20240293399-A1 GASTRO-RESISTANT HIGH-STRENGTH FORMULATION CONTAINING POSACONAZOLE ALFRED E. TIEFENBACHER GMBH & CO. KG (DE) 2024-09-05 US claimed
EP-4091604-B1 GRANULES CONTAINING POSACONAZOLE TIEFENBACHER ALFRED E GMBH & CO KG (DE) 2024-04-03 EP claimed
US-20240016753-A1 PHARMACEUTICAL COMPOSITIONS FERRING B.V. (NL) 2024-01-18 US claimed
WO-2023228116-A1 INTRANASAL ADMINISTRATION OF THERMOSTABLE RNA VACCINES ACCESS TO ADVANCED HEALTH INSTITUTE (US) 2023-11-30 WO claimed
EP-4275678-A1 METHOD FOR PREPARING TABLET OF PHARMACEUTICAL COMPOSITION COMPRISING TRIAZOLOPYRAZINE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT Abion Inc. (KR) 2023-11-15 EP claimed
US-20230255893-A1 FORMULATION TO DELIVER LIPOPHILIC ACTIVE INGREDIENTS PERFORMS S.R.L. (IT) 2023-08-17 US claimed
WO-2000003680-A2 EMOLLIENT ESTERS BASED UPON CAPRYL ALCOHOL AND ISOSTEARIC ACID BERNEL CHEMICAL COMPANY, INC. (US) 2000-01-27 WO claimed
US-6001341-A Deodorant and/or antiperspirant cosmetic compositions CONDEA AUGUSTA S.P.A. (IT) 1999-12-14 US claimed
WO-1999047128-A1 BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1999-09-23 WO claimed
US-5795695-A PHOTO-QUALITY RECORDING XEROX CORPORATION (US) 1998-08-18 US claimed
EP-0492747-B1 Pharmaceutical preparation for topical application ROEMMERS SA (AR) 1996-03-20 EP claimed
EP-0270503-B1 UTILIZATION OF BROMURE D'OTILONIUM (DCI) FOR TOPIC APPLICATION IN THE GASTROINTESTINAL TRACT AND RELATIVE PHARMACEUTICAL FORMULATION APPROPRIATE FOR SUCH USE A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1993-09-15 EP claimed
EP-0270503-A2 Utilization of bromure d'otilonium (DCI) for topic application in the gastrointestinal tract and relative pharmaceutical formulation appropriate for such use A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1988-06-08 EP claimed
EP-0186453-A2 A non-irritating cleansing composition WARNER-LAMBERT COMPANY (US) 1986-07-02 EP claimed
US-4490395-A BLEND OF ISOBUTYLENE-ISOPRENE COPOLYMER, POLYUINYLACETATE, GLCERYL MONOSTEARATE AND WAYES WARNER-LAMBERT COMPANY (US) 1984-12-25 US claimed
US-4182686-A ONE STEP EMULSION OF A FATTY ACID, AN ALKANOLAMINE, CETYL ALCOHOL, GLYCEROL MONOSTEARATE, AN ABRASIVE AND AN ACRYLIC RESIN FILLER Laks, Sid (US) 1980-01-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12611407-B2 Gastro-resistant high-strength formulation containing posaconazole RICTOR, CYP51A1, SI GPR84 3295/4885FFAR1 250/4885MAPT 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.